The Chinese medicine sector performed actively, with Teda Pharmaceutical and Panlong Pharmaceutical hitting the daily limit. Bio Valley rose over 15%, Longshen Rongfa and Yue Wannianqing increased over 10%, while Datang Pharmaceutical, Zhendong Pharmaceutical, and Foci Pharmaceutical also gained. In related ETFs, Chinese medicine ETF (560080) rose 2.06%, with a trading volume of 9.9477 million yuan. On the news front, the Ministry of Industry and Information Technology and seven other departments issued the “Implementation Plan for High-Quality Development of the Chinese Medicine Industry (2026–2030),” which proposes that by 2030, a preliminary formation of a collaborative development system for the entire Chinese medicine industry chain will be achieved.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
The traditional Chinese medicine sector performed actively, with Tedi Pharmaceutical and Panlong Pharmaceutical hitting the daily limit.
The Chinese medicine sector performed actively, with Teda Pharmaceutical and Panlong Pharmaceutical hitting the daily limit. Bio Valley rose over 15%, Longshen Rongfa and Yue Wannianqing increased over 10%, while Datang Pharmaceutical, Zhendong Pharmaceutical, and Foci Pharmaceutical also gained. In related ETFs, Chinese medicine ETF (560080) rose 2.06%, with a trading volume of 9.9477 million yuan. On the news front, the Ministry of Industry and Information Technology and seven other departments issued the “Implementation Plan for High-Quality Development of the Chinese Medicine Industry (2026–2030),” which proposes that by 2030, a preliminary formation of a collaborative development system for the entire Chinese medicine industry chain will be achieved.